Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection
Abstract Humans get SARS-CoV-2 infection mainly through inhalation; thus, vaccine that induces protective immunity at the virus entry site is important for early control of the infection. In this study, two anionic liposome (L)-adjuvanted VLP vaccines against SARS-CoV-2 were formulated. Baculovirus-...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-11-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-79122-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850061821185097728 |
|---|---|
| author | Monrat Chulanetra Primana Punnakitikashem Kodchakorn Mahasongkram Wanpen Chaicumpa Kantaphon Glab-ampai |
| author_facet | Monrat Chulanetra Primana Punnakitikashem Kodchakorn Mahasongkram Wanpen Chaicumpa Kantaphon Glab-ampai |
| author_sort | Monrat Chulanetra |
| collection | DOAJ |
| description | Abstract Humans get SARS-CoV-2 infection mainly through inhalation; thus, vaccine that induces protective immunity at the virus entry site is important for early control of the infection. In this study, two anionic liposome (L)-adjuvanted VLP vaccines against SARS-CoV-2 were formulated. Baculovirus-Sf21 insect cell system was used for production of VLPs made of full-length S, M and E proteins. S protein of one vaccine (L-SME-VLPs) contained furin cleavage site at the S1/S2 junction, while that of another vaccine (L-S′ME-VLPs) did not. Both vaccines were innocuous and immunogenic when administered IP and IN to mice. Mice immunized IP with L-SME-VLPs/L-S′ME-VLPs (three doses, two-weeks intervals) had serum virus neutralizing (VN) antibodies (in falling order of isotype frequency): IgG3, IgA and IgG2a/IgG3, IgA and IgM, respectively. The L-S′ME VLPs vaccine induced significantly higher serum VN antibody titers than the L-SME-VLPs vaccine. All mice immunized IN with both vaccines had significant rise of VN antibodies in their bronchoalveolar lavage fluids (BALF). The VN antibodies in 67% of immunized mice were Th1- isotypes (IgG2a and/or IgG2b); the immunized mice had also other antibody isotypes in BALF. The intranasal L-S′ME-VLPs should be tested further step-by-step towards the clinical use as effective and safe vaccine against SARS-CoV-2. |
| format | Article |
| id | doaj-art-904db75aff65495c8a60a9bbec2c4943 |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-904db75aff65495c8a60a9bbec2c49432025-08-20T02:50:05ZengNature PortfolioScientific Reports2045-23222024-11-0114111810.1038/s41598-024-79122-7Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infectionMonrat Chulanetra0Primana Punnakitikashem1Kodchakorn Mahasongkram2Wanpen Chaicumpa3Kantaphon Glab-ampai4Department of Parasitology, Center of Research Excellence in Therapeutic Proteins and Antibody Engineering, Faculty of Medicine Siriraj Hospital, Mahidol UniversityDepartment of Biochemistry, Faculty of Medicine Siriraj Hospital, Mahidol UniversityDepartment of Parasitology, Center of Research Excellence in Therapeutic Proteins and Antibody Engineering, Faculty of Medicine Siriraj Hospital, Mahidol UniversityDepartment of Parasitology, Center of Research Excellence in Therapeutic Proteins and Antibody Engineering, Faculty of Medicine Siriraj Hospital, Mahidol UniversityDepartment of Parasitology, Center of Research Excellence in Therapeutic Proteins and Antibody Engineering, Faculty of Medicine Siriraj Hospital, Mahidol UniversityAbstract Humans get SARS-CoV-2 infection mainly through inhalation; thus, vaccine that induces protective immunity at the virus entry site is important for early control of the infection. In this study, two anionic liposome (L)-adjuvanted VLP vaccines against SARS-CoV-2 were formulated. Baculovirus-Sf21 insect cell system was used for production of VLPs made of full-length S, M and E proteins. S protein of one vaccine (L-SME-VLPs) contained furin cleavage site at the S1/S2 junction, while that of another vaccine (L-S′ME-VLPs) did not. Both vaccines were innocuous and immunogenic when administered IP and IN to mice. Mice immunized IP with L-SME-VLPs/L-S′ME-VLPs (three doses, two-weeks intervals) had serum virus neutralizing (VN) antibodies (in falling order of isotype frequency): IgG3, IgA and IgG2a/IgG3, IgA and IgM, respectively. The L-S′ME VLPs vaccine induced significantly higher serum VN antibody titers than the L-SME-VLPs vaccine. All mice immunized IN with both vaccines had significant rise of VN antibodies in their bronchoalveolar lavage fluids (BALF). The VN antibodies in 67% of immunized mice were Th1- isotypes (IgG2a and/or IgG2b); the immunized mice had also other antibody isotypes in BALF. The intranasal L-S′ME-VLPs should be tested further step-by-step towards the clinical use as effective and safe vaccine against SARS-CoV-2.https://doi.org/10.1038/s41598-024-79122-7Baculovirus-insect cell systemCOVID-19LiposomeSARS-CoV-2Virus-like particlesVLP vaccines |
| spellingShingle | Monrat Chulanetra Primana Punnakitikashem Kodchakorn Mahasongkram Wanpen Chaicumpa Kantaphon Glab-ampai Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection Scientific Reports Baculovirus-insect cell system COVID-19 Liposome SARS-CoV-2 Virus-like particles VLP vaccines |
| title | Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection |
| title_full | Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection |
| title_fullStr | Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection |
| title_full_unstemmed | Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection |
| title_short | Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection |
| title_sort | immunogenicity of intraperitoneal and intranasal liposome adjuvanted vlp vaccines against sars cov 2 infection |
| topic | Baculovirus-insect cell system COVID-19 Liposome SARS-CoV-2 Virus-like particles VLP vaccines |
| url | https://doi.org/10.1038/s41598-024-79122-7 |
| work_keys_str_mv | AT monratchulanetra immunogenicityofintraperitonealandintranasalliposomeadjuvantedvlpvaccinesagainstsarscov2infection AT primanapunnakitikashem immunogenicityofintraperitonealandintranasalliposomeadjuvantedvlpvaccinesagainstsarscov2infection AT kodchakornmahasongkram immunogenicityofintraperitonealandintranasalliposomeadjuvantedvlpvaccinesagainstsarscov2infection AT wanpenchaicumpa immunogenicityofintraperitonealandintranasalliposomeadjuvantedvlpvaccinesagainstsarscov2infection AT kantaphonglabampai immunogenicityofintraperitonealandintranasalliposomeadjuvantedvlpvaccinesagainstsarscov2infection |